- Anticoagulation therapies help prevent blood clots, reducing the risk of stroke, heart attacks, and venous thromboembolism. These therapies have become essential in managing cardiovascular and hematological disorders, especially among the elderly and high-risk patient groups.
- In Europe, demand for anticoagulation therapy is rising due to better diagnostic practices, higher awareness of atrial fibrillation-related complications, and the favorable reimbursement frameworks across Western Europe.
- Germany is expected to dominate the Europe Anticoagulation Therapy market due to its strong healthcare infrastructure, early adoption of DOACs, and robust clinical trial network.
- The UK is anticipated to register the highest CAGR due to national guidelines recommending DOACs over traditional therapies, e-prescription systems, and increased NHS spending on stroke prevention.
- Direct Oral Anticoagulants (DOACs) segment is expected to hold the largest share of 53.2% due to their predictable pharmacokinetics, reduced need for monitoring, and broad clinical adoption.
